Skip to main content

Structural Heart Disease

TIO 2023 – Atrioventricular Valve Replacement Beyond TEER?
  • 1.00 EBAC

Learning objectives

  • Compare the utility of repair and replacement valve technology in mitral regurgitation
  • Individualise valve choice for aortic regurgitation based on valve durability and patient features
  • Recall the utility and limitations of specialty balloons
  • Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
  • Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
  • Identify suitable patients for interatrial shunting
  • Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
See more
HCM in Review: Highlights of 2022
  • 0.25 AMA PRA Credit

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments
  • Summarise results from ongoing trials with experimental treatments
See more
HCM in Review: Assessing SCD Risk in HCM & Managing HCM With High Risk SCD
  • 0.50 AMA PRA Credit

Learning objectives

  • Recall risk factors associated with sudden cardiac death (SCD)
  • Recall best practice approaches to prevent SCD according to guidelines and expert insight
  • Stratify patients likely to benefit from invasive procedures versus pharmacological treatment
See more
Severe Aortic Stenosis: Stratifying Patients for Lifetime Management
  • 1.00 EBAC

Learning objectives

  • Describe the challenges with lifetime management in severe AS in both a SAVR and TAVI-first scenario
  • Summarise clinical evidence for TAVI in low surgical risk patients
  • Recall different guideline recommendations for SAVR and TAVI approaches
  • Assimilate current clinical knowledge with patient preferences when formulating treatment plans for severe AS patient
See more
HCM in Review: ESC–HFA 2022 & How to Differentiate HCM From Its Phenocopies
  • 0.50 AMA PRA Credit

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments and summarise results from ongoing trials with experimental treatments
  • Differentiate the signs and symptoms of HCM from other conditions that frequently mask, or mimic the disease and in the presence of comorbidities
See more
HCM in Review: Highlights of ACC 2022
  • 0.25 AMA PRA Credit

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments
  • Summarise results from ongoing trials with experimental treatments
See more